AstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh
International Biofarmautic Company’s office building of Astrazeneca.
Cfoto | Future Publishing | Getty Images
Astrazeneca On Monday, the US is planning to invest $ 50 billion to support its production and research capabilities, which has become the latest pharmaceutical company that increased its expenditures in the state after the US trade tariffs.
Headquartered Cambridge, the Anglo Swedish biotechnology company in the UK, the commitment of the commitment of the commitment of the commitment, including Oral GLP-1 obesity pill, including weight management and metabolic portfolio to produce a new billion dollar facility, he said.
Planned for Virginia Commonwealth, the facility will be the largest production investment of Astrazeneca in the world and to optimize production, “AI, automation and data analysis will benefit.”
The latest financing will also expand research and development and cell therapy in Maryland, Massachusetts, California, Indiana and Texas and create “tens of thousands of jobs”.
CEO Pascal Soriot, the commitment supports the company’s “faith in America’s innovation in biofarmasaltics”, and will support the ambition of reaching $ 80 billion annually until 2030, half of the US is expected to come from the US.
Astrazeneca, which has developed one of the key Covid-19 vaccines by developing international headlines, has been prioritizing the US market for a long time. In 2024, the United States made more than 40% of the company’s annual income.
In November, Astrazeneca announced a US investment of $ 3.5 billion shortly after the US Presidential elections. At the beginning of this month, Times said that the company could carry its list from London to the United States, and that analysts would be a major blow to British public markets.
Astrazeneca is the most valuable job listed in London’s FTSE 100. The company refused to comment on the Times report.
Pharmaceutical companies increased US spending
Astrazeneca’s financing announcement follows similar movements of global pharmaceutical companies – Novartis, Sanofi and Roche and US-based Eli Lilly and Johnson & Johnson-Son-last months, US President Donald Trump promised to increase US investments due to domestic manufacturing demands.
The industry expects more clarity on the Trump administration’s drug tariffs and the final result of the 232 investigation into the sector at the end of this month. The effort to re -balance US drug prices with other countries is continuing.
At the beginning of this month, Trump claimed that the industry could face up to 200%and a short period of 12-18 months to allow companies to carry the production of the state. However, many companies and analysts called the time frame inadequate.
“It is typically a three to four -year horizon for most drugs. We are working hard to accelerate as quickly as possible and show that we are planning our planned investments,” Vas Narasimhan, CEO of Novartis CEO.
